ATE552031T1 - Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz - Google Patents

Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz

Info

Publication number
ATE552031T1
ATE552031T1 AT02787266T AT02787266T ATE552031T1 AT E552031 T1 ATE552031 T1 AT E552031T1 AT 02787266 T AT02787266 T AT 02787266T AT 02787266 T AT02787266 T AT 02787266T AT E552031 T1 ATE552031 T1 AT E552031T1
Authority
AT
Austria
Prior art keywords
compositions containing
treatment
pharmaceutical compositions
insulin resistance
containing non
Prior art date
Application number
AT02787266T
Other languages
English (en)
Inventor
Ezio Ghigo
Der Lely Aart Jan Van
Original Assignee
Alize Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alize Pharma Sas filed Critical Alize Pharma Sas
Application granted granted Critical
Publication of ATE552031T1 publication Critical patent/ATE552031T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02787266T 2001-12-18 2002-12-18 Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz ATE552031T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2365704 2001-12-18
PCT/CA2002/001964 WO2003051389A2 (en) 2001-12-18 2002-12-18 Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof

Publications (1)

Publication Number Publication Date
ATE552031T1 true ATE552031T1 (de) 2012-04-15

Family

ID=4170909

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787266T ATE552031T1 (de) 2001-12-18 2002-12-18 Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz

Country Status (7)

Country Link
US (1) US7485620B2 (de)
EP (1) EP1455814B1 (de)
JP (1) JP4562394B2 (de)
AT (1) ATE552031T1 (de)
AU (1) AU2002351593A1 (de)
ES (1) ES2383796T3 (de)
WO (1) WO2003051389A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
KR20050027168A (ko) * 2002-07-19 2005-03-17 사이토스 바이오테크놀로지 아게 그렐린-캐리어 컨쥬게이트
US7825090B2 (en) * 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance
WO2005097173A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
EP1814916A2 (de) * 2004-11-15 2007-08-08 Eli Lilly And Company Desacyl-ghrelin-antiköper und deren therapeutische anwendungen
EP1862173B1 (de) * 2005-02-23 2014-12-17 Kyoto University Promotor der regeneration einer pankreatischen zelle und promotor der insulinproduktion in einer pankreatischen zelle
EP1757290A1 (de) 2005-08-16 2007-02-28 Zentaris GmbH Triazolderivate als Liganden der Wachstumshormonrezeptoren
EP1937262B1 (de) 2005-09-29 2019-05-08 Ipsen Pharma Zusammensetzung zur verwendung in der behandlung von gastrointestinaler dysmotilität
EP1818061A1 (de) * 2005-12-02 2007-08-15 Charite-Universitätsmedizin Berlin Verwendung von Ghrelin zur Stimulierung des Haarwachstums
US8653022B2 (en) 2006-03-28 2014-02-18 Liat Mintz Use of ghrelin splice variant for treating hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or coronary heart disease and/or weight management and/or diabetes and/or hyperglycemia
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
AU2008257448B9 (en) * 2007-05-31 2013-07-11 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
EP2067481A1 (de) 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutische Verwendung von Desacylghrelin
US8476408B2 (en) 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
WO2010099296A1 (en) 2009-02-26 2010-09-02 Transposagen Biopharmaceuticals, Inc. Hyperactive piggybac transposases
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
EP2431035A1 (de) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Neue Triazolderivate mit verbesserter Rezeptoraktivität und Bioverfügbarkeitseigenschaften als Ghrelin-Antagonisten der Wachstumshormon-Sekretagogum-Rezeptoren
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
PL2790721T3 (pl) 2011-12-15 2019-05-31 Millendo Therapeutics Sas Fragmenty nieacylowanej greliny do zastosowania do leczenia zespołu pradera-williego
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
US20160151458A1 (en) 2013-06-21 2016-06-02 Alize Pharma Sas Use Of Unacylated Ghrelin, Fragments And Analogs Thereof As Antioxidant
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
EP1286697A2 (de) 2000-05-17 2003-03-05 Eli Lilly And Company Methode zur selektiven hemmung der aktivität von ghrelin
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
CN100411683C (zh) 2002-05-21 2008-08-20 阿斯比奥制药株式会社 含有生长素释放肽的药物组合物
US7825090B2 (en) 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance

Also Published As

Publication number Publication date
JP2005511771A (ja) 2005-04-28
EP1455814B1 (de) 2012-04-04
WO2003051389A3 (en) 2003-09-12
US7485620B2 (en) 2009-02-03
WO2003051389A2 (en) 2003-06-26
AU2002351593A1 (en) 2003-06-30
EP1455814A2 (de) 2004-09-15
ES2383796T3 (es) 2012-06-26
JP4562394B2 (ja) 2010-10-13
US20050080007A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
ATE552031T1 (de) Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
EP1196444B8 (de) Exendin-4 konjugate und ihre medizinische verwendung
AU2002305450A1 (en) Proteomimetic compounds and methods
WO2007128817A3 (en) Insulin derivative
AP1763A (en) Pulmonary administration of chemically modified insulin
DE60028970D1 (de) An her2 bindende peptidverbindungen
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
WO2003075850A3 (en) Methods for alzheimer's disease treatment and cognitive enhancement
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
WO2004019884A3 (en) Agents and methods for enhancing bone formation
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
WO2006137100A3 (en) Molecular complex comprising arbutine, ascorbic acid, oleuropeina or its derivatives thereof and related uses in medical field
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
SE0102147D0 (sv) New methods
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
PL1622939T3 (pl) Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
AU2003260436A1 (en) Pyrimidine compounds